Latest News

Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium





WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY–Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Symposia

Source link





Related posts

Most people who smoke e-cigarettes want to quit, finds study

Newsemia

Scientists bring new hope to brain tumor patients

Newsemia

Opinion: Oncologists are guardedly optimistic about AI. But will it drive real improvements in cancer care?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy